pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,937 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1875Endpoints1455Fierce Biotech771BioSpace762BioPharma Dive550raps249onclive165fda recalls
therapy area
allOncology12965Rare Disease3357Immunology3052Cardiology2859Hematology2304Pulmonology2255Vaccines
  • FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolio
    Regeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
    Endpoints · 3h agoApprovalPositive↗ source
  • Isomorphic Labs partners with Merck on AI-driven oncology drug discovery after $5 billion funding round
    Isomorphic Labs announced a new collaboration with Merck & Co., adding the pharma giant to its AI drug discovery partners. The agreement follows Isomorphic's recent $5 billion financing and will f…
    Fierce Biotech · 8h agoDealPositive↗ source
← prev
page 1 of 118
next →
120
fda medwatch115
globenewswire health73
fda press62
1861
Psychiatry & CNS1234
Ophthalmology1138
Endocrinology & Metabolism809
Pain792
Nephrology787
  • AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor deal
    AbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…
    Endpoints · 10h agoDealPositive↗ source
  • Novartis CEO says shareholders remain supportive despite recent trial setbacks
    Novartis chief executive Vas Narasimhan told Fierce that, despite a series of recent clinical setbacks, most shareholders continue to back the company’s long-term strategy. The setbacks include th…
    Fierce Biotech · 13h agoPositive↗ source
  • Novartis reports mid-stage eczema drug success, plans to restart autoimmune CAR-T trials and narrows sales growth outlook
    Novartis said its experimental eczema treatment achieved a positive result in a mid-stage study, marking the company's first major clinical milestone in the skin-disorder area this year. The compa…
    Endpoints · 1h agoPositive readoutNeutral↗ source
  • nChroma Bio cuts workforce by half and stops HBV cure trial
    nChroma Bio, a Boston biotech focused on epigenetic therapies, announced it is reducing its staff by roughly half. The reduction follows the decision to halt enrollment in its phase 1/2 study of C…
    Fierce Biotech · 8h agoLayoffsNegative↗ source
  • Outset Medical issues safety alert for Tablo dialysis system power cords overheat risk
    The FDA’s Center for Devices and Radiological Health has posted an Early Alert after learning that certain power cords used with Outset Medical’s Tablo hemodialysis consoles and the TabloCart with…
    fda medwatch · 12h agoRegulatoryNeutral↗ source
  • Eli Lilly pilots virtual clinician platform to speed Alzheimer’s diagnosis
    Eli Lilly is testing a new virtual‑clinician service aimed at accelerating the diagnosis and early care for people showing signs of Alzheimer’s disease. The approach allows individuals with memory…
    Endpoints · 3h agoPositive↗ source
  • Evaxion Biotech Shifts R&D Focus Exclusively to Cancer Vaccines, Halts Infectious and Autoimmune Programs
    Evaxion Biotech announced it is ending its infectious disease and autoimmune research programs to concentrate solely on oncology. The company’s most advanced candidate is EVX-01, a therapeutic can…
    Fierce Biotech · 7h agoNeutral↗ source
  • Teva R&D chief Eric Hughes resigns as company pushes innovative medicines expansion
    Teva Pharmaceutical announced that its head of research and development, Eric Hughes, M.D., Ph.D., will resign, with his departure set to occur over the next few months. Hughes joined Teva in 2022…
    Fierce Biotech · 11h agoNeutral↗ source
  • Chinese AI lab MegaRobo raises nearly $200M; Isomorphic partners with Merck
    Plus news about Adcendo, Biohaven, Sellas, Yuanshi, VitriVax and Ansa Biotechnologies. MegaRobo raises nearly $200 million: The Chinese AI and lab-automation company announced the raise in a post o…
    Endpoints · 47m ago↗ source
  • Sanofi considering a deal to acquire Insmed, according to report
    Sanofi is looking at a deal to buy the US drugmaker Insmed, Bloomberg News reported Thursday, in what would be one of the biggest biopharma takeovers of the last several years. The Bloomberg report…
    Endpoints · 51m ago↗ source
  • Why Oura is buying Counsel
    Every year at HLTH, there is usually one piece of news that everyone has an opinion about. This year, it was Oura buying Counsel Health. That’s for good reason. It’s been rare to see a ...
    Endpoints · 1h ago↗ source
  • Majority rate home diagnostic tests ‘very helpful,’ but just 33% for accuracy: DNV survey
    People are twice as likely to describe home diagnostic tests as very helpful versus them as very accurate, according to new global research from the quality assurance, risk management and certifica…
    Fierce Biotech · 17h ago↗ source
  • FDA approves Infilbray, first therapy for neurological symptoms of Type 3 Gaucher disease
    The U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets for treating the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15…
    fda press · 22h agoApprovalPositive↗ source
  • Pfizer signs $2.6 billion deal with China's Starna to acquire in vivo CAR-T programs for autoimmune diseases
    Pfizer announced a $2.6 billion agreement with Chinese biotech Starna Therapeutics to obtain rights to three preclinical in vivo CAR-T candidates aimed at autoimmune diseases. The deal includes a…
    Fierce Biotech · 1d agoDealPositive↗ source
  • AI bio startup Boltz secures $110 million Series A as AI drug design platform usage surges
    Boltz, an artificial‑intelligence driven biotech startup, announced a $110 million Series A financing round less than a year after emerging from stealth with an initial $28 million investment. The…
    Endpoints · 1d agoDealPositive↗ source
  • AbbVie inks up to $2.5 billion deal with Disco to pursue bispecific cancer therapeutics
    AbbVie announced a collaboration with German biotech Disco Pharmaceuticals that could be worth up to $2.5 billion. The agreement provides a $40 million upfront payment, with the balance linked to…
    Fierce Biotech · 1d agoDealPositive↗ source
  • Biogen's tau antisense therapy shows 38% slower decline in 2-year Alzheimer extension study
    Biogen presented new data from the open‑label extension of its phase 2 Celia trial at the CTAD 2026 conference. The update focused on the tau‑targeting antisense oligonucleotide, diranersen, admini…
    Fierce Biotech · 1d agoPositive readoutPositive↗ source
  • Priavoid’s Alzheimer’s drug misses primary goal in phase 2 trial, shows later cognitive benefit signal
    German biotech Priavoid reported that its oral all-D-peptide candidate, PRI-002, did not achieve the primary efficacy endpoint in the phase 2 PRImus-AD study of patients with mild cognitive impairm…
    Fierce Biotech · 1d agoNegative readoutNegative↗ source
  • Cognito Therapeutics' Phase 3 HOPE Study Misses Primary Goal but Shows Promise in Mild Alzheimer’s Patients
    Cognito Therapeutics announced that its phase 3 HOPE trial of Spectris AD, a home-based device delivering light and sound stimulation, did not achieve its primary efficacy endpoint. The trial enro…
    Fierce Biotech · 1d agoNegative readoutNeutral↗ source
  • nChroma Bio halts sole clinical trial and cuts staff by half
    Two Boston-area biotech founders merged their companies a few years ago to create nChroma Bio, hoping the combined effort would weather a weak market for genetic‑medicine firms. The company has no…
    Endpoints · 20h agoLayoffsNegative↗ source
  • Pfizer licenses three in vivo CAR-T assets from Starna for $330 million to target autoimmune disease outside Greater China
    Pfizer announced a licensing agreement with Starna Therapeutics, a Chinese biotech, to acquire exclusive rights to three pre-IND in vivo CAR-T programs aimed at autoimmune diseases. Under the deal…
    Endpoints · 1d agoDealPositive↗ source
  • Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchase
    Merck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…
    Endpoints · 1d agoDealNegative↗ source
  • FDA clears Medtronic's MiniMed Fit tubeless insulin pump
    MiniMed, a Medtronic unit, announced that the FDA has granted clearance for its new tubeless insulin pump called MiniMed Fit. The device is designed to be worn for up to seven days and holds a 300…
    Fierce Biotech · 1d agoApprovalPositive↗ source